Abbott will commercialize HDC’s diagnostics, and Quest Diagnostics will leverage the firm’s biomarkers for a new test.
Health Discovery (HDC) inked two separate agreements related to its prostate cancer diagnostic program. It has given Abbott the right to commercialize its gene-based tests for clinically significant prostate cancer.
Abbott acquired coexclusive clinical laboratory rights and exclusive in vitro diagnostic rights for HDC’s tissue-based and urine-based prostate cancer test.
Additionally, HDC licensed rights to Quest Diagnostics for the development of a urine-based test for clinically significant prostate cancer. Under the terms of this agreement, HDC will receive payments, royalties, and additional undisclosed financial considerations.
—
To comment on this story, go to BLOGbiotech.